GlaxoSmithKline
GSK
49.80
-0.93
-1.82%
GlaxoSmithKline
US · GSK
#177 by market cap
Listed 1970
-1.82%
49.80
-0.93
-1.82%
Live - 304 symbols - heartbeat 452s ago
· 2026-09-23 15:50
Pre-market
50.22
-0.99%
After-hours
50.72
0.00%
Overnight
50.28
-0.87%
- Market cap
- 99.76B
- P/E (TTM)i
- 15.84
- P/Bi
- 4.24
- EPSi
- 3.71
- Div yieldi
- 3.56%
- 52W posi
- 51%
Reader sentiment
Are you bullish or bearish on GSK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
Near fair value
30.34
fair value ≈ 51.34
72.34
- Implied fair-value range of 30.34-72.34, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -3.0% below the average-multiple fair value of 51.34.
Valuation each multiple against its own 5-year range
P/B ratio
4.34
Cheap vs history
30th percentile
5-year average 4.71 · #8 of 18 in Drug Manufacturers - General
P/E ratio
16.22
In line with history
63rd percentile
5-year average 13.86 · forward 13.17 · #4 of 15 in Drug Manufacturers - General
P/S ratio
2.31
Expensive vs history
80th percentile
5-year average 2.05 · forward 2.21 · #6 of 18 in Drug Manufacturers - General
Vs. peers Drug Manufacturers - General
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| GlaxoSmithKline (GSK) | 99.76B | 15.84 | 4.24 | 3.56% |
| Eli Lilly and Co (LLY) | 1.09T | 38.76 | 32.09 | 0.56% |
| Johnson & Johnson (JNJ) | 646.86B | 31.14 | 7.61 | 1.95% |
| AbbVie (ABBV) | 468.83B | 74.95 | -78.98 | 2.54% |
| Merck & Co (MRK) | 365.73B | 118.59 | 8.72 | 2.27% |
| Novartis AG (NVS) | 271.17B | 21.55 | 6.53 | 3.32% |
Other StockVane-tracked companies in the same industry.
Morningstar
★★★☆☆
Fair value48.98
Economic moatWide
UncertaintyMedium
Trading 1.6% above Morningstar's fair value estimate.
Economic moat
The company's excess returns on capital and superb profitability, which could persist for decades or more, warrant a wide economic moat rating. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.
Quote time 2026-09-23 15:50:01 · For reference only, not investment advice.